AML

Aprea Therapeutics Presents Data From Phase 1/2 Trial of Eprenetapopt (APR-246) in Advanced Solid Tumors at ESMO Congress 2021

Monday, September 20, 2021 - 9:15pm

As of the July 31, 2021 data cutoff, 33 patients were enrolled on study and 31 had initiated treatment.

Key Points: 
  • As of the July 31, 2021 data cutoff, 33 patients were enrolled on study and 31 had initiated treatment.
  • Patients in the NSCLC Phase II cohort were required to have prior exposure to a PD-1 or PD-L1 inhibitor.
  • The trial continues to enroll and treat patients and exploratory studies involving analyses of patient-derived immune cell populations are ongoing.
  • The Companys lead product candidate is eprenetapopt (APR-246), a small molecule in clinical development for hematologic malignancies and solid tumors.

Wilshire, in Association with the Financial Times, Launches Digital Asset Indexes to Bring More Reliable Data to Investors

Monday, September 20, 2021 - 2:38pm

Wilshires proprietary methodology will apply to both individual digital assets and indexes covering over 85% of the market capitalization on eligible exchanges.

Key Points: 
  • Wilshires proprietary methodology will apply to both individual digital assets and indexes covering over 85% of the market capitalization on eligible exchanges.
  • This rigorous and innovative approach offers higher levels of data transparency and establishes a set of credible benchmarks.
  • We look forward to working closely with the Financial Times and Wilshire to provide our trusted digital asset data to build these innovative products offering institutional investors new avenues for digital asset exposure.
  • CryptoCompare is a global leader in digital asset data providing institutional and retail investors with real-time and historical data spanning 5,500+ coins and 250,000+ currency pairs.

RevoluGROUP Canada Inc. Sendity White Label Launch and Corporate Update

Monday, September 20, 2021 - 1:00pm

VANCOUVER, British Columbia, Sept. 20, 2021 (GLOBE NEWSWIRE) -- RevoluGROUP Canada Inc. (TSX-V: REVO ) (Frankfurt: IJA2 ) (the "Company") is pleased to announce that the first White Label within the remittance sector launches today under the brand Sendity .

Key Points: 
  • VANCOUVER, British Columbia, Sept. 20, 2021 (GLOBE NEWSWIRE) -- RevoluGROUP Canada Inc. (TSX-V: REVO ) (Frankfurt: IJA2 ) (the "Company") is pleased to announce that the first White Label within the remittance sector launches today under the brand Sendity .
  • Further to the news release datedthe 15th of June 2021 , the white-label partner platform is branded Sendity .
  • RevoluPAY management received confirmation from the DCE management team on the 8th of September 2021 confirming that they intend to launch within the previously informed timeframe.
  • For further information on RevoluGROUP Canada Inc. (TSX-V: REVO), visit the Company's website at www.RevoluGROUP.com .

Moleculin to Present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit

Friday, September 17, 2021 - 1:05pm

HOUSTON, Sept. 17, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that Walter Klemp, President and Chief Executive Officer of Moleculin, will present at the virtual Oppenheimer Fall Healthcare Life Sciences and MedTech Summit on September 20, 2021 at 4:35 PM ET.

Key Points: 
  • HOUSTON, Sept. 17, 2021 /PRNewswire/ --Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that Walter Klemp, President and Chief Executive Officer of Moleculin, will present at the virtual Oppenheimer Fall Healthcare Life Sciences and MedTech Summit on September 20, 2021 at 4:35 PM ET.
  • The live webcast of the presentation will be accessible on the the Events page in the Investors section of the Company's website ( www.moleculin.com ).
  • The Company's lead program, Annamycin is a next-generation anthracycline designed to be noncardiotoxic and to avoid multidrug resistance mechanisms.
  • For more information about the Company, please visit www.moleculin.com and connect on Twitter , LinkedIn and Facebook .

Worldwide Identity Verification Industry to 2026 - Growth, Trends, COVID-19 Impact and Forecasts - ResearchAndMarkets.com

Thursday, September 16, 2021 - 10:39pm

It is one of the highly regulated, governed industries, and it is also prone to identity frauds that augment the demand.

Key Points: 
  • It is one of the highly regulated, governed industries, and it is also prone to identity frauds that augment the demand.
  • Banks and financial service providers, including pension and insurance providers, have a stringent identity and personal data requirements, often known as the 'Know Your Customer (KYC) requirements.
  • The growing fintech investments worldwide are expected to influence the adoption of identity verifications as competition increases and vendors intensely focus on gaining new customers.
  • In 2020, the Singaporean government launched the SingPass digital identity platform, which allows secure digital signatures for property caveats.

Biomea Fusion Announces FDA Clearance of Investigational New Drug Application for Irreversible Menin Inhibitor BMF-219

Thursday, September 16, 2021 - 6:35pm

Food and Drug Administration(FDA) has cleared the company's Investigational New Drug application to begin a Phase I trial of BMF-219, a selective irreversible menin inhibitor, in adult patients with relapsed or refractory acute leukemia including those with an MLL/KM2TA gene rearrangement or NPM1 mutation.

Key Points: 
  • Food and Drug Administration(FDA) has cleared the company's Investigational New Drug application to begin a Phase I trial of BMF-219, a selective irreversible menin inhibitor, in adult patients with relapsed or refractory acute leukemia including those with an MLL/KM2TA gene rearrangement or NPM1 mutation.
  • This is just the beginning for BMF-219 as we are planning to pursue multiple indications with our novel molecule.
  • This is also just the beginning for the company, as we continue to make significant progress with our pipeline programs.
  • Biomea Fusion is a biopharmaceutical company focused on the discovery, development and commercialization of irreversible small molecules to treat patients with genetically defined cancers.

Socure Announces Industry-First Predictive Document and Identity Verification Solution with Unparalleled Precision and Multi-Dimensional Risk Insights

Thursday, September 16, 2021 - 2:15pm

Socure , the leading provider of digital identity verification and fraud solutions, announced the industrys first predictive document and identity verification solution with native fraud risk signals and intelligence.

Key Points: 
  • Socure , the leading provider of digital identity verification and fraud solutions, announced the industrys first predictive document and identity verification solution with native fraud risk signals and intelligence.
  • With Socures Predictive Document Verification solution, hundreds of validation checks are performed on every document and selfie resulting in unrivaled auto-decision rates and risk insights.
  • Socures Predictive Document Verification helps us onboard new customers quickly and scale more rapidly than we could with other tools.
  • The hundreds of predictive signals incorporated into the document verification and biometric matching process provide the industrys only digital identity continuum measuring against fraud risk.

Intellia Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug Application for NTLA-5001, its CRISPR/Cas9-Engineered TCR-T Cell Candidate for Acute Myeloid Leukemia

Thursday, September 16, 2021 - 12:30pm

NTLA-5001 is an autologous T cell receptor (TCR)-T cell therapy engineered to target the Wilms Tumor (WT1) antigen for the treatment of all genetic subtypes of acute myeloid leukemia (AML).

Key Points: 
  • NTLA-5001 is an autologous T cell receptor (TCR)-T cell therapy engineered to target the Wilms Tumor (WT1) antigen for the treatment of all genetic subtypes of acute myeloid leukemia (AML).
  • AML is the most common type of acute leukemia in adults, that, despite currently available treatments, has a five-year survival rate of less than 30 percent.
  • Acute myeloid leukemia (AML) is a cancer of the blood and bone marrow that is rapidly fatal without immediate treatment.
  • NTLA-5001 is a CRISPR/Cas9-engineered T cell receptor (TCR)-T cell therapy in development for the treatment of all genetic subtypes of acute myeloid leukemia (AML).

COVID-19 Scoop: Epoch-Making GoldenBiotech's Oral COVID-19 New Drug Trial Got Green Light from the FDA to Extend Recruiting Severe COVID-19 Patients

Thursday, September 16, 2021 - 11:05am

The total trial subjects will remain the same, 174 patients in total.

Key Points: 
  • The total trial subjects will remain the same, 174 patients in total.
  • The trial recruiting is expedited in full swing covering the USA, Peru and Argentina where the new upheaval pandemic is rampant with highly transmitted SARS-CoV2 variants.
  • "So far, there is no oral drug approved or receives the EUA from the FDA for COVID-19 treatment.
  • It also received the ODD for the treatment of Pancreatic Cancer from European EMA in 2017.

Euroclear completes acquisition of MFEX Group

Thursday, September 16, 2021 - 8:00am

BRUSSELS and STOCKHOLM, Sept. 16, 2021 /PRNewswire/ -- Euroclear is pleased to announce its acquisition of MFEX Group, a leading global digital fund distribution platform, completed yesterday.

Key Points: 
  • BRUSSELS and STOCKHOLM, Sept. 16, 2021 /PRNewswire/ -- Euroclear is pleased to announce its acquisition of MFEX Group, a leading global digital fund distribution platform, completed yesterday.
  • Lieve Mostrey, Chief Executive Officer, Euroclear commented: "We are delighted to have completed the acquisition of MFEX Group.
  • The Euroclear group comprises Euroclear Bank, the International CSD, as well as Euroclear Belgium, Euroclear Finland, Euroclear France, Euroclear Nederland, Euroclear Sweden and Euroclear UK & International.
  • In September 2021, MFEX became a part of the Euroclear group - one of the world's largest providers of domestic and cross-border settlement and related services for bond, equity, ETF and mutual fund transactions.